Efficacy and safety of the noradrenaline reuptake inhibitor, TAS‐303, in women with stress urinary incontinence: Results of a double‐blind, randomized, placebo‐controlled, early phase II trial

OBJECTIVE: To carry out an exploratory assessment of the efficacy and safety of TAS‐303, a noradrenaline reuptake inhibitor, in women with stress urinary incontinence. METHODS: In a double‐blind, placebo‐controlled, early phase II study, women with stress urinary incontinence and stress urinary inco...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Satoru, Kato, Kumiko, Takei, Mineo, Yokoyama, Osamu, Gotoh, Momokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles: Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821236/
https://www.ncbi.nlm.nih.gov/pubmed/33145841
http://dx.doi.org/10.1111/iju.14411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821236/
https://www.ncbi.nlm.nih.gov/pubmed/33145841
http://dx.doi.org/10.1111/iju.14411

Ejemplares similares